Guided Therapeutics (GTHP) Receivables (2010 - 2025)

Guided Therapeutics has disclosed Receivables across 16 years of filings, most recently posting $4000.0 for Q4 2025.

• Receivables for Q4 2025 came in at $4000.0, up 33.33% year-over-year; the trailing twelve-month figure through Dec 2025 was $4000.0 (up 33.33% YoY), and the FY2025 annual result was $4000.0, up 49.87% from the prior year.
• Receivables came in at $4000.0 for Q4 2025 at Guided Therapeutics, down from $6000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $165.1 million in Q1 2022 to a low of $2000.0 in Q1 2025.
• The 5-year median for Receivables is $8471.0 (2023), against an average of $23.3 million.
• Across the five-year window, Receivables soared 130955.56% in 2022 and tumbled 99.97% in 2023, its largest moves.
• Guided Therapeutics' Receivables stood at $171153.0 in 2021, then declined by 23.47% to $130984.0 in 2022, then tumbled by 94.32% to $7442.0 in 2023, then slumped by 59.69% to $3000.0 in 2024, then surged by 33.33% to $4000.0 in 2025.
• The last three Receivables figures came in at $4000.0 (Q4 2025), $6000.0 (Q3 2025), and $8000.0 (Q2 2025), per Business Quant data.